Spots Global Cancer Trial Database for epidermal growth factor receptor wild type
Every month we try and update this database with for epidermal growth factor receptor wild type cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04427072 | Carcinoma, Non-... | Capmatinib Docetaxel | 18 Years - | Novartis | |
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04427072 | Carcinoma, Non-... | Capmatinib Docetaxel | 18 Years - | Novartis | |
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04427072 | Carcinoma, Non-... | Capmatinib Docetaxel | 18 Years - | Novartis | |
Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04677595 | Non-Small Cell ... | Capmatinib | 18 Years - | Novartis | |
Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04677595 | Non-Small Cell ... | Capmatinib | 18 Years - | Novartis | |
Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer | NCT03647488 | Carcinoma, Non-... | Capmatinib Spartalizumab Docetaxel | 18 Years - | Novartis |